AstraZeneca (LON:AZN) Receives “Buy” Rating from Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZNGet Rating)‘s stock had its “buy” rating reiterated by equities research analysts at Deutsche Bank Aktiengesellschaft in a research report issued on Wednesday, reports. They presently have a £115 ($149.62) price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective would suggest a potential upside of 9.84% from the company’s current price.

Several other equities analysts have also recently weighed in on the stock. Deutsche Bank Rese… set a £115 ($149.62) price objective on shares of AstraZeneca in a research report on Wednesday, April 6th. Jefferies Financial Group set a GBX 9,500 ($123.60) price objective on shares of AstraZeneca in a research report on Tuesday. The Goldman Sachs Group set a GBX 6,950 ($90.42) price objective on shares of AstraZeneca in a research report on Thursday, February 10th. Berenberg Bank lifted their price objective on shares of AstraZeneca from £100 ($130.11) to £120 ($156.13) and gave the stock a “buy” rating in a research report on Monday, April 11th. Finally, Credit Suisse Group set a £110 ($143.12) target price on shares of AstraZeneca in a research note on Friday, April 8th. Two investment analysts have rated the stock with a sell rating and twelve have assigned a buy rating to the company’s stock. According to data from, the company has an average rating of “Buy” and an average price target of £104.36 ($135.78).

LON AZN opened at £104.70 ($136.22) on Wednesday. AstraZeneca has a twelve month low of GBX 7,392 ($96.17) and a twelve month high of £110 ($143.12). The company has a debt-to-equity ratio of 82.58, a quick ratio of 0.67 and a current ratio of 1.16. The stock has a market cap of £162.23 billion and a price-to-earnings ratio of 1,716.81. The firm’s 50 day moving average price is GBX 9,565.30 and its two-hundred day moving average price is GBX 8,975.81.

AstraZeneca Company Profile (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Recommended Stories

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.